Secondary Prevention Using Cholesterol-Lowering Medications in Patients with Prior Atherosclerotic Cardiovascular Disease Events: A Retrospective Cohort Analysis
**Background:** Secondary prevention with lipid-lowering medications in patients with atherosclerotic cardiovascular disease (ASCVD) is known to reduce the risk of clinical events and death. Current guidelines codify recommendations for implementing secondary prevention in appropriate patients. Howe...
Saved in:
Main Authors: | Xue Han, Steven Fox, Michelle Chu, Jeff McCombs |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2022-01-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/001c.28934 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multimorbidity in Atherosclerotic Cardiovascular Disease and Its Associations With Adverse Cardiovascular Events and Healthcare Costs: A Real-World Evidence Study
by: Dingwei Dai, et al.
Published: (2024-03-01) -
Heart groups in South Africa advocate for tighter LDL-C control and lipoprotein(a) testing to curb atherosclerotic cardiovascular disease
by: E Q Klug, et al.
Published: (2024-05-01) -
Does the consumption of soya products affect cholesterol levels, blood pressure, or other cardiovascular health indicators?
by: Aleksandra Walendzik, et al.
Published: (2025-02-01) -
The association between TyG index and cardiovascular mortality is modified by antidiabetic or lipid-lowering agent: a prospective cohort study
by: Changchang Fang, et al.
Published: (2025-02-01) -
Pharmacological regression of atherosclerotic plaque in patients with type 2 diabetes
by: Loredana Bucciarelli, et al.
Published: (2025-03-01)